UT-15C SR

DRUG4 trials

Sponsors

United Therapeutics

Conditions

Pulmonary Arterial HypertensionPulmonary Hypertension

Phase 2

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

CompletedNCT01477333

United TherapeuticsPulmonary Arterial Hypertension

Start: 2011-10-31End: 2013-11-30Updated: 2023-12-27

Remodulin® to Oral Treprostinil Transition

CompletedNCT01588405

United TherapeuticsPulmonary Arterial Hypertension

Start: 2012-04-30End: 2014-12-31Updated: 2016-05-16

Phase 3

Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension

CompletedNCT00887978

United TherapeuticsPulmonary Hypertension

Start: 2009-06-30End: 2011-07-31Updated: 2013-01-15

A Pharmacokinetic Substudy of the TDE-PH-304 Protocol

CompletedNCT01934582

United TherapeuticsPulmonary Arterial Hypertension

Start: 2013-08-31End: 2013-11-30Updated: 2024-01-03

Related Papers

Relevance of Angiopoietin‐2 and Soluble P‐Selectin Levels in Patients with Pulmonary Arterial Hypertension Receiving Combination Therapy with Oral Treprostinil: A FREEDOM‐C2 Biomarker Substudy

Pulmonary Circulation2016-07-269 citations

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.

2013-09-01221 citations